Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop

Thrombosis and Haemostasis

Volumn 79, Issue 3, 1998, Pages 597-601

  Debrock, Sophie ^a   Declerck, Paul J ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Faculty of Pharmaceutical Sciences   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECONDARY STRUCTURE;

EID: 0031936528     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614952     Document Type: Article

References (33)

1. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld A-J, Van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986; 5: 2539-44.
2. Ny T, Sawdey M, Lawrence D, Milan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
3. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Danø K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-80.
4. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type 1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-8.
5. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587.
6. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE. Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992: 355: 270-3.
7. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-6.
8. Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen activator inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
9. Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
10. Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-66.
11. van Zonneveld A-J, van den Berg BMM, van Meijer M, Pannekoek H. Identification of functional interaction sites on proteins using bacteriophage-displayed random epitope libraries. Gene 1995; 167: 49-52.
12. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
13. Gils A, Knockaert I, Declerck PJ. Substrate behaviour of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 1996; 35: 7474-81.
14. Debrock S, Declerck PJ. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor 1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. FEBS Lett 1995; 376: 243-6.
15. Ey PL, Prowse SJ, Jenkins CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978; 15: 429-36.
16. Barbas III CF, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 1991; 88: 7978-82.
17. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd Ed, New York: Cold Spring Harbor. NY, 1989.
18. Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
19. Declerck PJ, Verstreken M, Collen D. Measurement of different forms of plasminogen activator inhibitor 1 (PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. Fibrinolysis 1990; 4, Suppl. 2: 132-3.
20. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost 1985; 54: 684-7.
21. Gettins P, Patson PA, Shapira M. The role of conformational change in serpin structure and function. Bioessays 1993; 15: 461-4.
22. Hood DB, Huntington JA, Getting PG. Alpha 1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry 1994; 33: 8538-47.
23. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem 1994; 269: 27657-62.
24. Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang J-Y, Kristensen P, Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells: inhibitor neutralizing and one-step affinity purification. Thromb Haemost 1986; 55: 206-12.
25. Keijer J, Linders M, van Zonneveld A-J, Ehrlich HJ, de Boer J-P, Pannekoek H. The interaction of plasminogen activator inhibitor-1 (PAI-1) with plasminogen activators (t-PA, u-PA) and fibrin: localization of interaction sites and physiological relevance. Blood 1991; 78: 401-9.
26. MacGregor IR, Tonner AM, Micklem LR, James K, Booth NA. Murine monoclonal antibodies against active site epitopes on human endothelial plasminogen activator inhibitor (PAI-1). Fibrinolysis 1990; 4: 27-34.
27. Perrie AM, MacGregor IR, Booth NA. Definition of epitopes within plasminogen activator inhibitor type-1 (PAI-1) using multiple peptide synthesis. Fibrinolysis 1993; 7: 257-63.
28. Van Meijer M, Klein Gebbink R, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor-1 (PAI-1). FEBS Lett 1994; 352: 342-6.
29. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-8.
30. Padmanabhan J, Sane DC. Localization of a vitronectin binding region on plasminogen activator inhibitor-1. Thromb Haemost 1995; 73: 829-34.
31. Declerck PJ, De Mol M, Alessi MC, Baudner S, Pâques EP, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-61.
32. Kraulis PJ. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991; 24: 946-50.
33. Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. A model of the reactive form of plasminogen activator inhibitor-1. J Struct Biol 1994; 113: 239-45.